


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) ~~Compounds~~ A Compound of formula (I):



wherein:

R₁ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or C₁-C₃ perfluoroalkyl, wherein the alkyl and cycloalkyl groups may be optionally substituted by halogen, -CN, C₁-C₆ alkoxy, -OH, -NH₂, or -NO₂;

R₂ is hydrogen, C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, thienyl, CH₂-thienyl, furanyl, CH₂-furanyl, oxazolyl, CH₂-oxazolyl, phenyl, benzyl, or CH₂-naphthyl; wherein the alkyl group and the rings of the cycloalkyl, thienyl, furanyl, oxazolyl, phenyl, benzyl, and naphthyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

R₃ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, or -CH₂-C₃-C₆ cycloalkyl;

R₄ is C₃-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, thienyl, CH₂-thienyl, furanyl, oxazolyl, phenyl, benzo[*b*]furan-2-yl, benzo[*b*]thien-2-yl, benzo[1,3]dioxol-5-yl, or naphthyl; wherein the alkyl group and the rings of the cycloalkyl, thienyl, furanyl, oxazolyl, phenyl, benzofuranyl, benzothienyl, and naphthyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃

perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

R₅ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, pyridinyl, -CH₂-pyridinyl, thienyl, CH₂-thienyl, furanyl, CH₂-furanyl, oxazolyl, CH₂-oxazolyl, phenyl, benzyl, benzo[*b*]furan-2-yl, benzo[*b*]thien-2-yl, benzo[1,3]dioxol-5-yl, naphthyl, CH₂-naphthyl, 9*H*-fluoren-1-yl, 9*H*-fluoren-4-yl, 9*H*-fluoren-9-yl, 9-fluorenone-1-yl, 9-fluorenone-2-yl, 9-fluorenone-4-yl, or CH₂-9*H*-fluoren-9-yl; wherein the alkyl group and the rings of the cycloalkyl, pyridinyl, thienyl, furanyl, oxazolyl, phenyl, benzyl, benzofuranyl, benzothienyl, naphthyl, fluorenyl, and fluorenone groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, -NO₂, or phenoxy, the phenoxy group being further optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, or C₁-C₃ perfluoroalkyl;


R₆ is hydrogen, C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, pyridyl, thienyl, CH₂-thienyl, furanyl, CH₂-furanyl, oxazolyl, CH₂-oxazolyl, phenyl, benzyl, benzo[*b*]furan-2-yl, benzo[*b*]thien-2-yl, benzo[1,3]dioxol-5-yl, CH₂-1-naphthyl, or CH₂-2-naphthyl; wherein the alkyl group and the rings of the cycloalkyl, thienyl, furanyl, oxazolyl, phenyl, benzyl, benzofuranyl, benzothienyl, and naphthyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

or R₅ and R₆ taken together may be C₃-C₆ cycloalkyl, 3-indan-1-yl, 1,2,3,4-tetrahydronaphthalen-1-yl, chroman-4-yl, 4*H*-chromen-4-yl, thiochroman-4-yl, 9*H*-fluoren-9-yl, 9,10-dihydroanthracen-9-yl, 9*H*-xanthen-9-yl, 9*H*-thioxanthen-9-yl, 6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-yl, or 10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5-yl, wherein these groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃

alkoxy, $-\text{OCHF}_2$, $-\text{CN}$, $-\text{COOH}$, $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{C}(\text{O})\text{OR}_7$, $-\text{C}(\text{O})\text{NH}_2$, $-\text{S}(\text{O})_2\text{CH}_3$, $-\text{OH}$, $-\text{NH}_2$, or $-\text{NO}_2$; and

R_7 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, $-\text{CH}_2$ - C_3 - C_6 cycloalkyl, or benzyl;
or a pharmaceutically acceptable salt or ester form thereof.


2. (Currently amended) The compound of claim 1 having the formula:



wherein R_1 - R_3 and R_5 - R_7 are as defined in Claim 1, and

R_4 is thienyl, furanyl, oxazolyl, phenyl, benzo[*b*]furan-2-yl, benzo[*b*]thien-2-yl, benzo[1,3]dioxol-5-yl, or naphthyl; wherein the rings of the thienyl, furanyl, oxazolyl, phenyl, benzofuranyl, benzothienyl, and naphthyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1 - C_3 alkyl, C_1 - C_3 perfluoroalkyl, $-\text{O}-\text{C}_1$ - C_3 perfluoroalkyl, $-\text{S}-\text{C}_1$ - C_3 perfluoroalkyl, C_1 - C_3 alkoxy, $-\text{OCHF}_2$, $-\text{CN}$, $-\text{COOH}$, $-\text{CH}_2\text{CO}_2\text{H}$, $-\text{C}(\text{O})\text{CH}_3$, $-\text{CO}_2\text{R}_8$, CO_2R_7 , $-\text{C}(\text{O})\text{NH}_2$, $-\text{S}(\text{O})_2\text{CH}_3$, $-\text{OH}$, $-\text{NH}_2$, or $-\text{NO}_2$;
or a pharmaceutically acceptable salt or ester form thereof.

3. (Currently amended) The compound of claim 1 having the formula II:



(II)

wherein:

R₁ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or C₁-C₃ perfluoroalkyl, wherein the alkyl and cycloalkyl groups may be optionally substituted by halogen, -CN, C₁-C₆ alkoxy, -OH, -NH₂, or -NO₂;

R₂ is hydrogen, C₁-C₈ alkyl, C₃-C₆ cycloalkyl, or -CH₂-C₃-C₆ cycloalkyl, wherein the alkyl group and the rings of the cycloalkyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

R₃ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, or -CH₂-C₃-C₆ cycloalkyl;

R₅ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, phenyl, benzyl, naphthyl, or CH₂-naphthyl, wherein the alkyl group and the rings of the cycloalkyl, phenyl, and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, -NO₂, or phenoxy; the phenoxy group being optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, or C₁-C₃ perfluoroalkyl; preferably -CF₃;


R₆ is hydrogen, C₁-C₈ alkyl, C₃-C₆ cycloalkyl, or -CH₂-C₃-C₆ cycloalkyl, wherein the alkyl group and the rings of the cycloalkyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

or R₅ and R₆ taken together may be a C₃-C₆ cycloalkyl group optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, ~~preferably CF₃~~, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, ~~preferably SCF₃~~, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

R₈, R₉, R₁₀ are each independently hydrogen, halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, ~~preferably CF₃~~, -O-C₁-C₃ perfluoroalkyl, ~~preferably OCF₃~~, -S-C₁-C₃ perfluoroalkyl, ~~preferably SCF₃~~, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

or a pharmaceutically acceptable salt or ester form thereof.

4. (Currently amended) The compound of claim I having the formula III:



III

wherein:

R₁ is hydrogen or C₁-C₆ alkyl;

R₂ is hydrogen or C₁-C₃ alkyl, optionally substituted by halogen;

R₅ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, phenyl, benzyl, or thienyl, wherein the alkyl group and the rings of the cycloalkyl, phenyl, thienyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ perfluoroalkyl, ~~preferably CF₃~~, -O-C₁-C₃ perfluoroalkyl, ~~preferably OCF₃~~, -S-C₁-C₃ perfluoroalkyl, ~~preferably SCF₃~~, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

R₆ is hydrogen or C₁-C₆ alkyl,

R₈, R₉, R₁₀ are each independently hydrogen, halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, ~~preferably -CF₃~~, -O-C₁-C₃ perfluoroalkyl, ~~preferably -OCF₃~~, -S-C₁-C₃ perfluoroalkyl, ~~preferably -SCF₃~~, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

or a pharmaceutically acceptable salt or ester form thereof.

5. (Original) The compound of claim I which is {5-(3-trifluoromethoxyphenyl)-3-[1-(4-trifluoromethylphenyl)-ethyl]-indol-1-yl}-acetic acid or a pharmaceutically acceptable salt or ester form thereof.

6. (Original) The compound of claim 1 which is {3-[3,5-bis(trifluoromethyl)benzyl]-5-[4-(trifluoromethoxy)phenyl]-1H-indol-1-yl}acetic acid or a pharmaceutically acceptable salt or ester form thereof.

7. (Original) The compound of claim 1 which is [3-[3,5-bis(trifluoromethyl)benzyl]-5-(2,4-dichlorophenyl)-1H-indol-1-yl]acetic acid or a pharmaceutically acceptable salt or ester form thereof.

8. (Original) The compound of claim 1 which is {3-[3,5-bis(trifluoromethyl)benzyl]-5-[3-(trifluoromethyl)phenyl]-1H-indol-1-yl}acetic acid or a pharmaceutically acceptable salt or ester form thereof.

9. (Original) The compound of claim 1 which is {5-(3-chlorophenyl)-3-[1-(2-thienyl)ethyl]-1H-indol-1-yl}acetic acid or a pharmaceutically acceptable salt or ester form thereof.

10. (Original) The compound of claim 1 which is [3-(1-phenylethyl)-5-(3-trifluoromethyl-phenyl)-indol-1-yl]acetic acid or a pharmaceutically acceptable salt or ester form thereof.

11. (Original) The compound of claim 1 which is [3-(1-thiophen-2-yl-ethyl)-5-(3-trifluoromethyl-phenyl)-indol-1-yl]acetic acid or a pharmaceutically acceptable salt or ester form thereof.

12. (Original) The compound of claim 1 which is [3-(1-cyclohexyl-ethyl)-5-(3-trifluoromethyl-phenyl)-indol-1-yl]acetic acid or a pharmaceutically acceptable salt or ester form thereof.

13. (Original) The compound of claim 1 which is [3-(4-isopropyl-benzyl)-5-(3-trifluoromethyl-phenyl)-indol-1-yl]acetic acid or a pharmaceutically acceptable salt or ester form thereof.

14. (Original) The compound of claim 1 which is [5-(2,4-dichloro-phenyl)-3-(1,3-dimethyl-butyl)-indol-1-yl]-acetic acid or a pharmaceutically acceptable salt or ester form thereof.


15. (Original) The compound of claim 1 which is [5-(2,4-dichloro-phenyl)-3-(1-phenyl-ethyl)-indol-1-yl]-acetic acid or a pharmaceutically acceptable salt or ester form thereof.

16. (Currently amended) The compound of claim 1 which is ~~[3-(1-cyclohexyl-ethyl)-5-(2,4-dichloro-phenyl)-indol-1-yl]-acetic acid~~ [3-(1-cyclohexyl-ethyl)-5-(2,4-dichloro-phenyl)-indol-1-yl]-acetic acid or a pharmaceutically acceptable salt or ester form thereof.

17. (Canceled)

18. (Original) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutical carrier.

19. (Withdrawn - Currently amended) A method for the treatment of thrombosis, ~~or~~ fibrinolytic impairment, peripheral arterial disease, stroke associated with or resulting from atrial fibrillation, myocardial ischemia, cardiovascular disease caused by noninsulin dependent diabetes mellitus, the formation of atherosclerotic plaques, chronic obstructive pulmonary disease, renal fibrosis, polycystic ovary syndrome, Alzheimer's disease, or cancer in a mammal, the method comprising administering to a mammal in need thereof, a therapeutically effective amount of a compound of ~~claim 1~~ formula I



(I)

wherein:

R₁ is hydrogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or C₁-C₃ perfluoroalkyl, wherein the alkyl and cycloalkyl groups are optionally substituted by halogen, -CN, C₁-C₆ alkoxy, -OH, -NH₂, or -NO₂;

R₂ is hydrogen, C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, thienyl, CH₂-thienyl, furanyl, CH₂-furanyl, oxazolyl, CH₂-oxazolyl, phenyl, benzyl, or CH₂-naphthyl, wherein the alkyl group and the rings of the cycloalkyl, thienyl, furanyl, oxazolyl, phenyl, benzyl, and naphthyl groups are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

R₃ is hydrogen, halogen, C₁-C₆ alkyl, C₁-C₃ perfluoroalkyl, C₁-C₆ alkoxy, C₃-C₆ cycloalkyl, or -CH₂-C₃-C₆ cycloalkyl;

R₄ is C₃-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, thienyl, CH₂-thienyl, furanyl, oxazolyl, phenyl, benzo[*b*]furan-2-yl, benzo[*b*]thien-2-yl, benzo[1,3]dioxol-5-yl, or naphthyl, wherein the alkyl group and the rings of the cycloalkyl, thienyl, furanyl, oxazolyl, phenyl, benzofuranyl, benzothienyl, and naphthyl groups are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

R₅ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, pyridinyl, -CH₂-pyridinyl, thienyl, CH₂-thienyl, furanyl, CH₂-furanyl, oxazolyl, CH₂-oxazolyl, phenyl, benzyl, benzo[*b*]furan-2-yl, benzo[*b*]thien-2-yl, benzo[1,3]dioxol-5-yl, naphthyl, CH₂-naphthyl, 9*H*-fluoren-1-yl, 9*H*-fluoren-4-yl, 9*H*-fluoren-9-yl, 9-fluorenone-1-yl, 9-fluorenone-2-yl, 9-fluorenone-4-yl, or CH₂-9*H*-fluoren-9-yl, wherein the alkyl group and the rings of the cycloalkyl, pyridinyl, thienyl, furanyl, oxazolyl, phenyl, benzyl, benzofuranyl, benzothienyl, naphthyl, fluorenyl, and fluorenone groups are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, phenoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂, wherein the phenoxy group is optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, or C₁-C₃ perfluoroalkyl;

R₆ is hydrogen, C₁-C₈ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, pyridyl, thienyl, CH₂-thienyl, furanyl, CH₂-furanyl, oxazolyl, CH₂-oxazolyl, phenyl, benzyl, benzo[*b*]furan-2-yl, benzo[*b*]thien-2-yl, benzo[1,3]dioxol-5-yl, CH₂-1-naphthyl, or CH₂-2-naphthyl, wherein the alkyl group and the rings of the cycloalkyl, thienyl, furanyl, oxazolyl, phenyl, benzyl, benzofuranyl, benzothienyl, and naphthyl groups are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂;

or R₅ and R₆ taken together may be C₃-C₆ cycloalkyl, 3-indan-1-yl, 1,2,3,4-tetrahydronaphthalen-1-yl, chroman-4-yl, 4*H*-chromen-4-yl, thiochroman-4-yl, 9*H*-fluoren-9-yl, 9,10-dihydroanthracen-9-yl, 9*H*-xanthen-9-yl, 9*H*-thioxanthen-9-yl, 6,7,8,9-tetrahydro-5*H*-benzocyclohepten-5-yl, or 10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5-yl, wherein these groups are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂; and

R₇ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, -CH₂-C₃-C₆ cycloalkyl, or benzyl;
or a pharmaceutically acceptable salt or ester form thereof.

20. (Withdrawn) A method of Claim 19 wherein the thrombosis or fibrinolytic impairment is associated with formation of atherosclerotic plaques, venous and arterial thrombosis, myocardial ischemia, atrial fibrillation, deep vein thrombosis, coagulation syndromes, pulmonary fibrosis, cerebral thrombosis, thromboembolic complications of surgery or peripheral arterial occlusion.

21. (Withdrawn - Currently amended) ~~A~~ The method of claim 19 wherein said method is for the treatment of peripheral arterial disease in a mammal, ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

22. (Withdrawn - Currently amended) ~~A~~ The method of claim 19 wherein said method is for the treatment of stroke associated with or resulting from atrial fibrillation in a mammal, ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

23. (Withdrawn - Currently amended) ~~A~~ The method of claim 19 wherein said method is for the treatment of deep vein thrombosis in a mammal, ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

24. (Withdrawn - Currently amended) ~~A~~ The method of claim 19 wherein said method is for the treatment of myocardial ischemia in a mammal, ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

25. (Withdrawn - Currently amended) ~~A~~ The method of claim 19 wherein said method is for the treatment of cardiovascular disease caused by noninsulin dependent diabetes mellitus in a mammal, ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

26. (Withdrawn - Currently amended) A The method of claim 19 wherein said method is for the treatment of the formation of atherosclerotic plaques in a mammal; ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

27. (Withdrawn - Currently amended) A The method of claim 19 wherein said method is for the treatment of chronic obstructive pulmonary disease in a mammal; ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

28. (Withdrawn - Currently amended) A The method of claim 19 wherein said method is for the treatment of renal fibrosis in a mammal; ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

29. (Withdrawn - Currently amended) A The method of claim 19 wherein said method is for the treatment of polycystic ovary syndrome in a mammal; ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

30. (Withdrawn - Currently amended) A The method of claim 19 wherein said method is for the treatment of Alzheimer's disease in a mammal; ~~comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.~~

31. (Withdrawn - Currently amended) A The method of claim 19 wherein said method is for the treatment of cancer in a mammal, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of Claim 1.

32. (New) The compound of claim 1 wherein R₄ is phenyl, wherein the rings of the phenyl group are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂.

33. (New) The compound of claim 3 wherein at least one of R₈, R₉, R₁₀ is independently halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃

perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂.


34. (New) The compound of claim 33 wherein R₅ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, or -CH₂-C₃-C₆ cycloalkyl, wherein the alkyl group and the rings of the cycloalkyl group are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, -NO₂, or phenoxy; the phenoxy group being optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, or C₁-C₃ perfluoroalkyl.

35. (New) The compound of claim 4 wherein at least one of R₈, R₉, R₁₀ is independently halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂.

36. (New) The compound of claim 35 wherein R₅ is C₁-C₈ alkyl, C₃-C₆ cycloalkyl, or -CH₂-C₃-C₆ cycloalkyl, wherein the alkyl group and the rings of the cycloalkyl group are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -CN, -COOH, -CH₂CO₂H, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, -NO₂, or phenoxy; the phenoxy group being optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, or C₁-C₃ perfluoroalkyl.

37. (New) The method of claim 19 wherein R₄ is phenyl, wherein the rings of the phenyl group are optionally substituted by from 1 to 3 groups selected from halogen, C₁-C₃ alkyl, C₁-C₃ perfluoroalkyl, -O-C₁-C₃ perfluoroalkyl, -S-C₁-C₃ perfluoroalkyl, C₁-C₃ alkoxy, -OCHF₂, -C(O)CH₃, -C(O)OR₇, -C(O)NH₂, -S(O)₂CH₃, -OH, -NH₂, or -NO₂.

38. (New) The method of claim 19 wherein the compound has the compound of formula III:



III

wherein:

R_1 is hydrogen or C_1 - C_6 alkyl;

R_2 is hydrogen or C_1 - C_3 alkyl, optionally substituted by halogen;

R_5 is C_1 - C_8 alkyl, C_3 - C_6 cycloalkyl, $-CH_2$ - C_3 - C_6 cycloalkyl, phenyl, benzyl, or thienyl, wherein the alkyl group and the rings of the cycloalkyl, phenyl, thienyl and benzyl groups may be optionally substituted by from 1 to 3 groups selected from halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 perfluoroalkyl, $-O$ - C_1 - C_3 perfluoroalkyl, $-S$ - C_1 - C_3 perfluoroalkyl, C_1 - C_3 alkoxy, $-OCHF_2$, $-CN$, $-COOH$, $-CH_2CO_2H$, $-C(O)CH_3$, $-C(O)NH_2$, $-S(O)_2CH_3$, $-OH$, $-NH_2$, or $-NO_2$;

R_6 is hydrogen or C_1 - C_6 alkyl,

R_8 , R_9 , R_{10} are each independently hydrogen, halogen, C_1 - C_3 alkyl, C_1 - C_3 perfluoroalkyl, $-O$ - C_1 - C_3 perfluoroalkyl, $-S$ - C_1 - C_3 perfluoroalkyl, C_1 - C_3 alkoxy, $-OCHF_2$, $-C(O)CH_3$, $-C(O)NH_2$, $-S(O)_2CH_3$, $-OH$, $-NH_2$, or $-NO_2$;
or a pharmaceutically acceptable salt or ester form thereof.

39. (New) The method of claim 38 wherein R_5 is C_1 - C_8 alkyl, C_3 - C_6 cycloalkyl, or $-CH_2$ - C_3 - C_6 cycloalkyl, wherein the alkyl group and the rings of the cycloalkyl group are optionally substituted by from 1 to 3 groups selected from halogen, C_1 - C_3 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_3 perfluoroalkyl, $-O$ - C_1 - C_3 perfluoroalkyl, $-S$ - C_1 - C_3 perfluoroalkyl, C_1 - C_3 alkoxy, $-OCHF_2$, $-CN$, $-COOH$, $-CH_2CO_2H$, $-C(O)CH_3$, $-C(O)NH_2$, $-S(O)_2CH_3$, $-OH$, $-NH_2$, or $-NO_2$.